keyword
MENU ▼
Read by QxMD icon Read
search

metronomic chemotherapy

keyword
https://www.readbyqxmd.com/read/28332584/akt-targeting-as-a-strategy-to-boost-chemotherapy-efficacy-in-non-small-cell-lung-cancer-through-metabolism-suppression
#1
Marion Le Grand, Raphael Berges, Eddy Pasquier, Marie-Pierre Montero, Laurence Borge, Alice Carrier, Sophie Vasseur, Veronique Bourgarel, Duje Buric, Nicolas André, Diane Braguer, Manon Carré
Metabolic reprogramming is a hallmark of cancer development, mediated by genetic and epigenetic alterations that may be pharmacologically targeted. Among oncogenes, the kinase Akt is commonly overexpressed in tumors and favors glycolysis, providing a rationale for using Akt inhibitors. Here, we addressed the question of whether and how inhibiting Akt activity could improve therapy of non-small cell lung cancer (NSCLC) that represents more than 80% of all lung cancer cases. First, we demonstrated that Akt inhibitors interacted synergistically with Microtubule-Targeting Agents (MTAs) and specifically in cancer cell lines, including those resistant to chemotherapy agents and anti-EGFR targeted therapies...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28331236/metronomic-chemotherapy-for-primary-non-metastatic-breast-cancer-a-systematic-review-of-the-literature
#2
Malgorzata Banys-Paluchowski, Eugen Ruckhäberle, Florian Schütz, Natalia Krawczyk, Tanja Fehm
Conventional chemotherapy is based on the "maximum tolerated dose" principle and aims at administering high doses of cytotoxic drugs followed by a rest period necessary for the body to recover. In the last decades alternative strategies have been developed to avoid serious side effects of conventional treatment, among them the metronomic chemotherapy. Much like a metronome keeps steady rhythm, metronomic therapy is administered continuously in low doses for a long time. In metastatic breast cancer, metronomic therapy is a valid option in pretreated or vulnerable patients and its use has recently been incorporated into various guidelines...
February 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28328969/oral-tegafur-uracil-as-metronomic-therapy-following-intravenous-folfox-for-stage-iii-colon-cancer
#3
Wen-Yen Huang, Ching-Liang Ho, Chia-Cheng Lee, Cheng-Wen Hsiao, Chang-Chieh Wu, Shu-Wen Jao, Jen-Fu Yang, Cheng-Hsiang Lo, Jia-Hong Chen
The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage III colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage III colon carcinomas treated with radical R0 resection were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/28323033/application-of-mathematical-models-to-metronomic-chemotherapy-what-can-be-inferred-from-minimal-parameterized-models
#4
Urszula Ledzewicz, Heinz Schättler
Metronomic chemotherapy refers to the frequent administration of chemotherapy at relatively low, minimally toxic doses without prolonged treatment interruptions. Different from conventional or maximum-tolerated-dose chemotherapy which aims at an eradication of all malignant cells, in a metronomic dosing the goal often lies in the long-term management of the disease when eradication proves elusive. Mathematical modeling and subsequent analysis (theoretical as well as numerical) have become an increasingly more valuable tool (in silico) both for determining conditions under which specific treatment strategies should be preferred and for numerically optimizing treatment regimens...
March 18, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28317239/the-use-of-low-dose-metronomic-chemotherapy-in-dogs-insight-into-a-modern-cancer-field
#5
REVIEW
T B Gaspar, J Henriques, L Marconato, F L Queiroga
The era of chemotherapy, which started in the middle of the last century, has been ruled by the routine use of dose-intense protocols, based on the "maximum-tolerated dose" concept. By promoting a balance between patient's quality of life and the goal of rapidly killing as many tumour cells as possible, these protocols still play a prominent role in veterinary oncology. However, with the opening of a new millennium, metronomic chemotherapy (MC) started to be considered a possible alternative to traditional dose-intense chemotherapy...
March 20, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28315702/editorial-metronomic-chemotherapy
#6
EDITORIAL
M N V Ravi Kumar, Anil K Sood
No abstract text is available yet for this article.
March 16, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28314176/metronomic-and-metronomic-like-therapies-in-neuroendocrine-tumors-rationale-and-clinical-perspectives
#7
REVIEW
Ioana Lambrescu, Simona Fica, Diana Martins, Francesca Spada, Chiara Cella, Emilio Bertani, Manila Rubino, Bianca Gibelli, Chiara Grana, Guido Bonomo, Luigi Funicelli, Davide Ravizza, Eleonora Pisa, Dario Zerini, Antonio Ungaro, Nicola Fazio
Metronomic therapy is characterized by the administration of regular low doses of certain drugs with very low toxicity. There have been numerous debates over the empirical approach of this regimen, but fewest side effects are always something to consider in order to improve patients' quality of life. Neuroendocrine tumors (NETs) are rare malignancies relatively slow-growing; therefore their treatment is often chronic, involving several different therapies for tumor growth control. Knowing that these tumors are highly vascularized, the anti-angiogenic aspect is highly regarded as something to be targeted in all patients harboring NETs...
February 24, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28296916/the-efficacy-and-toxicity-profile-of-metronomic-chemotherapy-for-metastatic-breast-cancer-a-meta-analysis
#8
Yangyang Liu, Feifei Gu, Jinyan Liang, Xiaomeng Dai, Chao Wan, Xiaohua Hong, Kai Zhang, Li Liu
PURPOSE: The current meta-analysis aimed to summarize the available evidence for the efficacy and serious adverse events (AEs) associated with use of metronomic chemotherapy (MCT) in patients with metastatic breast cancer (MBC). METHOD: Electronic databases (PubMed, EMBASE database, Web of Knowledge, and the Cochrane database) were systematically searched for articles related to the use of MCT in MBC patients. Eligible studies included clinical trials of MBC patients treated with MCT that presented sufficient data related to tumor response, progression-free survival (PFS), overall survival (OS), and grade 3/4 AEs...
2017: PloS One
https://www.readbyqxmd.com/read/28285686/pilot-phase-ii-study-of-metronomic-chemotherapy-in-combination-with-bevacizumab-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer
#9
Benjamin S Jones, Mary S Jerome, Deborah Miley, Bradford E Jackson, Mollie R DeShazo, Vishnu V B Reddy, Karan P Singh, Olivia C Brown, Francisco Robert
INTRODUCTION: The goal of this study was to explore the efficacy and tolerability of metronomic chemotherapy, a novel anti-angiogenic treatment strategy, in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Subjects with newly diagnosed stage IV NSCLC were treated with 4-week cycles of paclitaxel 80mg/m(2) and gemcitabine 300mg/m(2) weekly for three weeks, plus bevacizumab 10mg/kg every two weeks. Radiologic assessments were performed every 8 weeks...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28275392/clinical-response-in-patients-with-ovarian-cancer-treated-with-metronomic-chemotherapy
#10
Herman Andrés Perroud, O Graciela Scharovsky, Viviana Rosa Rozados, Carlos María Alasino
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28274890/metronomic-chemotherapy-in-metastatic-colorectal-cancer
#11
In Sook Woo, Yun Hwa Jung
Overall survival and quality of life of patients with metastatic colorectal cancer (mCRC) have improved due to the development of standard systemic treatment. However, many patients are still suffering from the eventual progression of cancer, treatment-related toxicities, and the economic burden of new drugs. Salvage or maintenance therapy, which consistently controls or stabilizes tumor progression without debilitating quality of life, is required. Recently, metronomic capecitabine maintenance therapy after disease control using conventional chemotherapy with maximal tolerated doses has demonstrated beneficial results in a phase III trial...
March 6, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28263383/results-of-a-randomized-prospective-clinical-trial-evaluating-metronomic-chemotherapy-in-nonmetastatic-patients-with-high-grade-operable-osteosarcomas-of-the-extremities-a-report-from-the-latin-american-group-of-osteosarcoma-treatment
#12
Andreza A Senerchia, Carla Renata Macedo, Sima Ferman, Marcelo Scopinaro, Walter Cacciavillano, Erica Boldrini, Vera Lúcia Lins de Moraes, Guadalupe Rey, Claudia T de Oliveira, Luis Castillo, Maria Tereza Almeida, Maria Luisa Borsato, Eduardo Lima, Daniel Lustosa, José Henrique Barreto, Tatiana El-Jaick, Simone Aguiar, Algemir Brunetto, Lauro Greggiani, Hugo Cogo-Moreira, Alvaro Atallah, Antonio Sergio Petrilli
BACKGROUND: Metronomic chemotherapy (MC) consists of the administration of a low dose of chemotherapy on a daily or weekly basis without a long break to achieve an antitumoral effect through an antiangiogenic effect or stimulation of the immune system. The potential effect of MC with continuous oral cyclophosphamide and methotrexate in patients with high-grade operable osteosarcomas (OSTs) of the extremities was investigated. METHODS: Patients with high-grade OSTs who were 30 years old or younger were eligible for registration at diagnosis...
May 15, 2017: Cancer
https://www.readbyqxmd.com/read/28259819/resistance-to-metronomic-chemotherapy-and-ways-to-overcome-it
#13
Maria Riesco-Martinez, Karla Parra, Ronak Saluja, Giulio Francia, Urban Emmenegger
Therapeutic resistance is amongst the major determinants of cancer mortality. Contrary to initial expectations, antivascular therapies are equally prone to inherent or acquired resistance as other cancer treatment modalities. However, studies into resistance to vascular endothelial growth factor pathway inhibitors revealed distinct mechanisms of resistance compared to conventional cytotoxic therapy. While some of these novel mechanisms of resistance also appear to be functional regarding metronomic chemotherapy, herein we summarize available evidence for mechanisms of resistance specifically described in the context of metronomic chemotherapy...
March 1, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28242865/metronomic-capecitabine-effectively-blocks-leptomeningeal-carcinomatosis-from-breast-cancer-a-case-report-and-literature-review
#14
REVIEW
Michela Maur, Claudia Omarini, Federico Piacentini, Annalisa Fontana, Elisa Pettorelli, Stefano Cascinu
BACKGROUND Meningeal carcinomatosis is a rare complication in breast cancer patients. At present, there are no defined guidelines for its management. The efficacy of systemic treatment seems to depend on its ability to cross the blood-brain-barrier and its interaction with tumor vasculature. Metronomic chemotherapy is a known modality of drug administration able to inhibit tumor angiogenesis. CASE REPORT We present a case of symptomatic leptomeningeal carcinomatosis from breast cancer successfully treated with capecitabine...
February 28, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28216371/atp-binding-cassette-transporters-in-tumor-endothelial-cells-and-resistance-to-metronomic-chemotherapy
#15
Kyoko Hida, Hiroshi Kikuchi, Nako Maishi, Yasuhiro Hida
Drug resistance is a major problem in anticancer therapy. ATP-binding cassette (ABC) transporters have a role in the multidrug resistance. A new regimen of chemotherapy has been proposed, called "metronomic chemotherapy". Metronomic chemotherapy is the frequent, regular administration of drug doses designed to maintain low, but active, concentrations of chemotherapeutic drugs over prolonged periods of time, without causing serious toxicities. Metronomic chemotherapy regimens were developed to optimize the antitumor efficacy of agents that target the tumor vasculature instead of tumor cells, and to reduce toxicity of antineoplastic drugs [1]...
February 16, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28202353/the-potential-clinical-promise-of-multimodality-metronomic-chemotherapy-revealed-by-preclinical-studies-of-metastatic-disease
#16
Robert S Kerbel, Yuval Shaked
We present a rationale for further clinical development and assessment of metronomic chemotherapy on the basis of unexpected results obtained in translational mouse models of cancer involving treatment of advanced metastatic disease. Historically, mouse cancer therapy models have been dominated by treating established primary tumors or early stage low volume microscopic disease. Treatment of primary tumors is also almost always the case when using genetically engineered mouse models (GEMMS) of cancer or patient-derived xenografts (PDXs)...
February 12, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28174262/role-of-vascular-normalization-in-benefit-from-metronomic-chemotherapy
#17
Fotios Mpekris, James W Baish, Triantafyllos Stylianopoulos, Rakesh K Jain
Metronomic dosing of chemotherapy-defined as frequent administration at lower doses-has been shown to be more efficacious than maximum tolerated dose treatment in preclinical studies, and is currently being tested in the clinic. Although multiple mechanisms of benefit from metronomic chemotherapy have been proposed, how these mechanisms are related to one another and which one is dominant for a given tumor-drug combination is not known. To this end, we have developed a mathematical model that incorporates various proposed mechanisms, and report here that improved function of tumor vessels is a key determinant of benefit from metronomic chemotherapy...
February 7, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28133740/toxicity-of-metronomic-cyclophosphamide-chemotherapy-in-a-uk-population-of-cancer-bearing-dogs-a-retrospective-study
#18
A Harper, L Blackwood
OBJECTIVES: The objective of this study was to assess the incidence of toxicity in a group of cancer-bearing dogs treated with metronomic chemotherapy. MATERIALS AND METHODS: Retrospective review of dogs treated with metronomic doses of cyclophosphamide: between 5 and 15 mg/m(2) /day or every other day for treatment of neoplasia. RESULTS: Of the 65 dogs included, there were signs of, mostly mild, toxicity in 32 (49%). The most common toxicities were sterile haemorrhagic cystitis (n=16) and gastrointestinal disorders (n=12)...
January 30, 2017: Journal of Small Animal Practice
https://www.readbyqxmd.com/read/28131905/safety-and-efficacy-study-of-metronomic-vinorelbine-cyclophosphamide-plus-capecitabine-in-metastatic-breast-cancer-a-phase-ii-trial
#19
Emilia Montagna, Antonella Palazzo, Patrick Maisonneuve, Giuseppe Cancello, Monica Iorfida, Angela Sciandivasci, Angela Esposito, Anna Cardillo, Manuelita Mazza, Elisabetta Munzone, Antonella Lai, Aron Goldhirsch, Marco Colleoni
In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (naïve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the naïve group and 65 in the pre-treated group were enrolled...
January 26, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28109908/potential-role-of-metronomic-chemotherapy-in-the-treatment-of-esophageal-and-gastroesophageal-cancer
#20
Vanita Noronha, Vijay M Patil, Amit Joshi, Anuradha Chougule, Shripad Banavali, Kumar Prabhash
Patients with esophagogastric cancer have poor prognoses in spite of the best available therapies. Patients are debilitated and may not tolerate, or may progress, on standard cytotoxic chemotherapy regimens. Metronomic chemotherapy is an attractive treatment option due to its very low reported toxicity, modest efficacy, low cost and ease of administration. Capecitabine is the most common drug used in metronomic scheduling; other drugs include cyclophosphamide and paclitaxel. Dosing of capecitabine can range from 1000 mg orally daily for 4 weeks on and 1 week off to a continuous dosing schedule of 1500 mg orally daily...
January 18, 2017: Cancer Letters
keyword
keyword
33012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"